SLC5A2 and metabolic dysfunction-associated steatohepatitis: This state-of-the-art review explores the current literature reporting the efficacy of SGLT-2 inhibitors in patients with type 2 diabetes and NASH and presents arguments for and against the use of SGLT-2 inhibitors in this patient population, where it plays a regulatory role in adipocyte differentiation, adipogenesis, and lipid metabolism.